An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression

Trial Profile

An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Esketamine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SUSTAIN-3
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 28 Jul 2017 Planned End Date changed from 31 Dec 2024 to 30 May 2025.
    • 11 Jul 2016 Planned End Date changed from 1 Aug 2021 to 1 Dec 2024.
    • 30 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top